Emerging Advances of Nanotechnology in Drug and Vaccine Delivery against Viral Associated Respiratory Infectious Diseases (VARID)
Open Access
- 28 June 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13), 6937
- https://doi.org/10.3390/ijms22136937
Abstract
Viral-associated respiratory infectious diseases are one of the most prominent subsets of respiratory failures, known as viral respiratory infections (VRI). VRIs are proceeded by an infection caused by viruses infecting the respiratory system. For the past 100 years, viral associated respiratory epidemics have been the most common cause of infectious disease worldwide. Due to several drawbacks of the current anti-viral treatments, such as drug resistance generation and non-targeting of viral proteins, the development of novel nanotherapeutic or nano-vaccine strategies can be considered essential. Due to their specific physical and biological properties, nanoparticles hold promising opportunities for both anti-viral treatments and vaccines against viral infections. Besides the specific physiological properties of the respiratory system, there is a significant demand for utilizing nano-designs in the production of vaccines or antiviral agents for airway-localized administration. SARS-CoV-2, as an immediate example of respiratory viruses, is an enveloped, positive-sense, single-stranded RNA virus belonging to the coronaviridae family. COVID-19 can lead to acute respiratory distress syndrome, similarly to other members of the coronaviridae. Hence, reviewing the current and past emerging nanotechnology-based medications on similar respiratory viral diseases can identify pathways towards generating novel SARS-CoV-2 nanotherapeutics and/or nano-vaccines.This publication has 219 references indexed in Scilit:
- Amphiphilic Polyanhydride Nanoparticles Stabilize Bacillus anthracis Protective AntigenMolecular Pharmaceutics, 2012
- Surfactant and its role in the pathobiology of pulmonary infectionMicrobes and Infection, 2012
- Rational Design of Pathogen-Mimicking Amphiphilic Materials as NanoadjuvantsScientific Reports, 2011
- Interplay between NS3 protease and human La protein regulates translation-replication switch of Hepatitis C virusScientific Reports, 2011
- Intranasal Immunization of Mice with a Bovine Respiratory Syncytial Virus Vaccine Induces Superior Immunity and Protection Compared to Those by Subcutaneous Delivery or Combinations of Intranasal and Subcutaneous Prime-Boost StrategiesClinical and Vaccine Immunology, 2010
- Rhesus Theta-Defensin Prevents Death in a Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Pulmonary DiseaseJournal of Virology, 2009
- Anionic Pulmonary Surfactant Phospholipids Inhibit Inflammatory Responses from Alveolar Macrophages and U937 Cells by Binding the Lipopolysaccharide-interacting Proteins CD14 and MD-2Online Journal of Public Health Informatics, 2009
- Peptide Nanoparticles as Novel Immunogens: Design and Analysis of a Prototypic Severe Acute Respiratory Syndrome VaccineChemical Biology & Drug Design, 2008
- Respiratory syncytial virus uses a Vps4-independent budding mechanism controlled by Rab11-FIP2Proceedings of the National Academy of Sciences of the United States of America, 2008
- Virus-Like Particle Vaccine Induces Protective Immunity against Homologous and Heterologous Strains of Influenza VirusJournal of Virology, 2007